Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, 
innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
We are pleased to share a blog post from Janssen’s Andreas Koester, M.D., Ph.D., Vice President, Innovation, Janssen Research & Development Operations.
As we celebrate Clinical Trial Awareness Week, it’s important for us to recognize patients as our partners in clinical trials – their participation is vital to our ability to bring new medicines to market. With this in mind, trial sponsors can do a better job listening to patients and addressing their needs to improve clinical trial experiences. In particular, we’re hearing more from patients that transparent access to clinical trial data such as laboratory results is high on their wish lists. At Janssen, as one part of our Patient Engagement initiative, we are working on ways to provide patients with access to their data from screening before any drug is administered or after a trial is over. We also want to take it one step further by finding ways to give patients access to some of their data while a clinical trial is still underway.
In today’s environment in which patients are becoming more active participants and decision-makers in their own healthcare, data is an important tool. Not only has research shown that patients who have easier access to their health data are more engaged, it’s ultimately the right thing to do. We’ve heard from patients that if the data comes from their bodies, they feel like they are entitled to receiving it in a timely manner and presented in a way that is easy to understand. They may also want to share certain data with doctors and loved ones. Sharing data is the way regulatory agencies are moving outside of clinical research, too. In 2014, the FDA amended the Clinical Laboratory Improvement Amendment of 1988 to give patients direct access to data when requested, instead of going through physicians.
Many patients see multiple providers, not just a trial investigator, so gaining timely access to their trial data may help patients better manage other health issues with their entire care team, as well as avoid repeat tests.
Of course, many trials are blinded and not all data can be shared during the blinded period. However, our philosophy at Janssen is that just because patients can’t receive all data collected, doesn’t mean they shouldn’t receive any of it. We’ve created a framework to consider, at the outset of a trial, what data can be shared with patients at what point in time. We are piloting our first program to enhance patient data access in a large-scale, multinational Phase III trial. This will help us give patients actionable healthcare information, moving them beyond the traditional role as “subjects” in trials toward treating them as true partners.
We commend other sponsors for paving the way by giving patients access to data once a trial is completed. We are hopeful that this trend signals a willingness across the pharmaceutical industry in making data available for patients more broadly.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
ICYMI: PhRMA submits comments to White House on artificial intelligence
New research: Industry sponsored clinical trials contribute billions to state economies
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
Decentralized clinical trials and the future of drug development
ICYMI: PhRMA CMO Dr. Michael Ybarra speaks with Dr. Fabian Sandoval about clinical trial diversity
PhRMA submits comments to OSTP on enhancing clinical trial diversity
Watch: Building trust and enhancing clinical trial diversity
PhRMA hosts first stakeholder workshop on clinical trial diversity
Increasing diversity at investigator sites could increase minority participation in clinical trials
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
Guest Post: Preserving clinical research sites during the coronavirus pandemic
The biopharmaceutical industry’s unique role in responding to COVID-19
COVID-19 Response: Supporting the frontline
America’s biopharmaceutical companies are working around the clock to beat coronavirus
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
Clinical Trials Awareness Week: Celebrating innovation in clinical research
Clinical trials impact state economies
Examining the truth behind clinical trial costs
New report details the setbacks and challenges to Alzheimer’s research
Guest post: Ensuring communities have a seat at the table: The importance of diversity in clinical trials
Bringing innovation to clinical trial design
EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing
Guest Post: Film chronicles clinical trials ‘paying it forward’
Biopharmaceutical industry policies aim to increase access to clinical trial data
Guest Post: The Clinical trial experience from a patient & researcher perspective
Guest Post: Spotlighting the heroes in clinical trials
Guest Post: Advancing oncology research through clinical trials
Clinical Trials Awareness Week: Celebrating the impact of clinical research
Driving innovation through collaboration
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Clinical Trials
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data
Guest Post: Patients as research partners - Rethinking patient access to clinical trial data